ADA: Once-weekly cagrilintide + semaglutide promising in type 2 diabetes
· Medical Xpressby Elana Gotkine
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Lead Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
reputable news agency
proofread
The GIST Add as preferred source
Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.
Vanita R. Aroda, M.D., from Brigham and Women's Hospital in Boston, and colleagues randomly assigned adults with type 2 diabetes inadequately controlled with diet and exercise to receive once-weekly subcutaneous cagrilintide 2.4 mg plus semaglutide 2.4 mg, cagrilintide 1.0 mg plus semaglutide 1.0 mg, or placebo for 40 weeks (62, 63, and 64 participants, respectively). The researchers found that the estimated mean change in hemoglobin A1c (HbA1c) after 40 weeks was −1.8, −1.5, and −0.1 percentage points for cagrilintide-semaglutide 2.4 mg each, 1.0 mg each, and placebo, respectively.
John B. Buse, M.D., from the University of North Carolina School of Medicine in Chapel Hill, and colleagues randomly assigned 2,713 adults with inadequately controlled type 2 diabetes receiving metformin with or without SGLT2i with overweight or obesity to receive cagrilintide-semaglutide, semaglutide, cagrilintide, or placebo for 68 weeks. The researchers found that the mean HbA1c change was significantly greater with cagrilintide-semaglutide (2.4 mg each) versus semaglutide 2.4 mg (−1.91 versus −1.75 percentage points).
In a third study, Julio Rosenstock, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues found that the mean HbA1c reductions were significantly greater with cagrilintide-semaglutide (2.4 mg each and 1.0 mg each: −2.33% and −2.10%, respectively) versus placebo (−0.66%) at week 40 in 274 adults with type 2 diabetes using basal insulin.
"These findings support a potential new therapeutic tool to effectively improve HbA1c levels well below 7% in such a challenging population," Rosenstock said in a statement.
Several authors from all three studies disclosed ties to biopharmaceutical companies, including Novo Nordisk, which is developing cagrilintide and funded the studies.
Publication details
Vanita R Aroda et al, Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study, The Lancet Diabetes & Endocrinology (2026). DOI: 10.1016/s2213-8587(26)00126-9
John B Buse et al, Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study, The Lancet Diabetes & Endocrinology (2026). DOI: 10.1016/s2213-8587(26)00125-7
Julio Rosenstock et al, Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study, The Lancet (2026). DOI: 10.1016/s0140-6736(26)01022-6
Journal information: The Lancet , The Lancet Diabetes & Endocrinology
Key medical concepts
Diabetes Type 2SemaglutideHemoglobin A, GlycatedSodium-Glucose Transporter 2 Inhibitors
Clinical categories
EndocrinologyClinical pharmacologyCommon illnesses & PreventionWeight management Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: ADA: Once-weekly cagrilintide + semaglutide promising in type 2 diabetes (2026, June 12) retrieved 12 June 2026 from https://medicalxpress.com/news/2026-06-ada-weekly-cagrilintide-semaglutide-diabetes.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.